Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer: a multi-institutional real-world analysis
Purpose Tarlatamab, a bispecific T-cell engager, has generated favorable response and survival outcomes in relapsed small cell lung cancer (SCLC). Factors